Medtronic Broadens Drug Delivery Options With EndoBionics Purchase
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's equity investment in privately held EndoBionics for injectable drug delivery technology complements Medtronic's existing drug-eluting stent platform
You may also be interested in...
Medtronic Vascular Sales Remain Steady Despite Cypher Competition
Myocardial cell replacement is among therapies Medtronic's vascular unit is striving to develop to curb reliance on coronary stent sales
Medtronic Vascular Sales Remain Steady Despite Cypher Competition
Myocardial cell replacement is among therapies Medtronic's vascular unit is striving to develop to curb reliance on coronary stent sales
Medinol Adopts “Trojan Horse” Strategy To Beat Drug-Eluting Stents
Medinol will begin pilot clinical trials by the end of 2002 on an anti-restenosis drug delivery technology intended as an alternative to drug-eluting stents